DAYBREAK quantifies retinal fluid monthly, after the loading phase, to individualize treatment DAYBREAK disease activity criteria • Presence of intraretinal fluid (IRF) in central 3mm 2 • Presence of subretinal fluid (SRF) in central 3mm 2 • Presence of macular hemorrhage Using a fluid tool provides meaningful advantages: 1. Optimizes treatment for each patient based on disease activity; patients treated only when they truly need it 2. Resembles retina specialists’ practice by using fluid volume to inform retreatment 3. Characterizes real-world durability potential 4/5/6-month durability potential High need patients treats until dry, enables monthly dosing and detects disease reactivations earlier Long durability patients allows patients without active disease to safely go to 6-month dosing 40